Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States


   Infocentre

Last Update: 04-02-2014  
Related category(ies):
Success stories  |  Special Collections

 

Countries involved in the project described in the article:
Italy
Add to PDF "basket"

The gold standard for cancer treatment

In the past, the best-known medical use of gold in the human body was probably limited to dental repairs, and even then considered by some to be a little ostentatious! But now, with the support of the EU, a multi-award-winning research project is demonstrating that gold can have unforeseen benefits in cancer treatment.

Photo of a gold nugget © Jeffrey Daly - Fotolia.com

Humanity’s battle against cancer is an unceasing one, and in recent years, new technologies have steadily improved the odds of beating the disease. According to the Organisation for Economic Cooperation and Development (OECD), the five-year survival rate for breast cancer in most member countries is now over 80 %.

One factor has been the more accurate targeting of tumour cells. For some 35 years, cisplatin and other platinum-based drugs have proved their ability to bind to DNA strands and destroy tumour cells. But doctors have discovered that they are not effective against all cancers; tumours tend to become resistant during lengthy treatment, and their toxicity can cause kidney failure and other systemic damage.

Professor Dolores Fregona and her research team at the University of Padua in Italy designed and tested gold compounds with the aim of “delivering the metal as a cytotoxic smart bomb” – killing off cancer cells while minimising the impact on other organs. Five years ago, they secured EU funding for the PEPMIDAS project, and launched a laboratory screening programme using cisplatin as the reference.

“The side effects of chemotherapy, in particular with platinum-based drugs, are a major drawback for patients,” says Professor Fregona. “Interestingly, our compounds show different action mechanisms.”

The team focused on two types of cancer: breast and prostate. Experiments on female mice bearing highly metastatic human breast cancer cells, using two gold compounds known as AuD6 and AuD8, revealed a 53 % reduction in cancer growth compared to the control treatment, within a month. Among the most responsive animals, the rate reached 85 %, with tumours actually shrinking in some.

And there was another striking result. “The mice appeared healthy and very active throughout the treatment. They showed neither fatigue nor weight loss, ruling out the onset of side effects due to chemotherapy,” explains the professor.

Furthermore, the team discovered that aggressive prostate cancer cells (resistant to cisplatin) were also sensitive to AuD8 and AuD9 gold derivatives, which successfully attacked diseased cells and slowed their proliferation, without any discernible toxic impact on lungs, spleen, liver or kidney.

International recognition

Prof. Fregona patented the technique in 2010, securing worldwide protection for her research findings. “The EU has been absolutely fundamental in allowing us to perform the in vitro and in vivo screenings of our compounds,” she acknowledges. “If I had not obtained financial support, I would not have been able to make the patent.”

In addition, the work has garnered a series of awards, both Italian and international. Prof. Fregona herself won the Belluno Women of Excellence prize in 2011. Her collaborator, 29-year-old PhD student Chiara Nardon, was named top young innovator in the field of biochemistry in 2013, and was able to exchange notes with the world’s most brilliant chemists at the Lindau Nobel Laureate Meeting in Germany.

But there is still some way to go. The team needs to secure enough backing to complete preclinical studies and launch the first phase of clinical trials. With this in mind, Prof. Fregona has already identified a private investor and is setting up a spin-off company, and may apply for further EU funding through the Horizon 2020 programme. Eventually she hopes to present the research to a pharmaceutical company in order to undertake the experimental phase among terminally ill cancer patients.

Project details

  • Project acronym: PERMIDAS
  • Participants: Italy (Coordinator)
  • FP6 Proj. N° 204828
  • Total costs: € 45 000
  • EU contribution: € 45 000
  • Duration: january 2008 to December 2010

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project web site

Project information on CORDIS

Contacts
Unit A1 - External & internal communication,
Directorate-General for Research & Innovation,
European Commission
Tel : +32 2 298 45 40
  Top   Research Information Center